Cyclacel Limited

Merck Sharp & Dohme (italia) S.p.a.

Giuseppe Remuzzi

Athos Gianella-Borradori

Ariela Benigni

Carla Zoja

The present invention relates to the use of an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease associated with antinuclear antibodies, wherein the inhibitor of CDK2 and/or CDK7 and/or CDK9 or pharmaceutically acceptable salt thereof is administered in an amount sufficient to down-regulate the levels of antinuclear antibodies. A further aspect of the invention relates to a combination comprising an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, and methylprednisolone, and its use in the treatment of diseases associated with antinuclear antibodies, such as SLE.

Purine and pyrimidine CDK inhibitors and their use for the treatment of autoimmune diseases

The present invention relates to the use, for the preparation of drugs to increase the survival rate of transplant patients, including renal and heart transplant patients, of a therapeutically effective amount of an angiotension II receptor antagonist compound, such as the class of substituted imidazoles represented by formula (I) and in particular by losartan potassium, 2-butyl-4-chloro-&lsqb;(2&prime;-tetrazol-5-yl)biphenyl-4-il&rsqb;methyl&rsqb;-5-(hydroxymethyl)imidazole potassium salt.

Growing community of inventors

Bergamo, Italy

Giuseppe Remuzzi